180 related articles for article (PubMed ID: 35190971)
21. Molecular oncogenesis of chondrosarcoma: impact for targeted treatment.
Speetjens FM; de Jong Y; Gelderblom H; Bovée JV
Curr Opin Oncol; 2016 Jul; 28(4):314-22. PubMed ID: 27166664
[TBL] [Abstract][Full Text] [Related]
22. Update on targets and novel treatment options for high-grade osteosarcoma and chondrosarcoma.
van Oosterwijk JG; Anninga JK; Gelderblom H; Cleton-Jansen AM; Bovée JV
Hematol Oncol Clin North Am; 2013 Oct; 27(5):1021-48. PubMed ID: 24093174
[TBL] [Abstract][Full Text] [Related]
23. The clinical management of chondrosarcoma.
Riedel RF; Larrier N; Dodd L; Kirsch D; Martinez S; Brigman BE
Curr Treat Options Oncol; 2009 Apr; 10(1-2):94-106. PubMed ID: 19238552
[TBL] [Abstract][Full Text] [Related]
24. Lysine-specific demethylase 1 (LSD1/KDM1A/AOF2/BHC110) is expressed and is an epigenetic drug target in chondrosarcoma, Ewing's sarcoma, osteosarcoma, and rhabdomyosarcoma.
Bennani-Baiti IM; Machado I; Llombart-Bosch A; Kovar H
Hum Pathol; 2012 Aug; 43(8):1300-7. PubMed ID: 22245111
[TBL] [Abstract][Full Text] [Related]
25. Phase 2 study of dasatinib in patients with alveolar soft part sarcoma, chondrosarcoma, chordoma, epithelioid sarcoma, or solitary fibrous tumor.
Schuetze SM; Bolejack V; Choy E; Ganjoo KN; Staddon AP; Chow WA; Tawbi HA; Samuels BL; Patel SR; von Mehren M; D'Amato G; Leu KM; Loeb DM; Forscher CA; Milhem MM; Rushing DA; Lucas DR; Chugh R; Reinke DK; Baker LH
Cancer; 2017 Jan; 123(1):90-97. PubMed ID: 27696380
[TBL] [Abstract][Full Text] [Related]
26. HDAC inhibitor-loaded bone cement for advanced local treatment of osteosarcoma and chondrosarcoma.
Tonak M; Becker M; Graf C; Eckhard L; Theobald M; Rommens PM; Wehler TC; Proschek D
Anticancer Res; 2014 Nov; 34(11):6459-66. PubMed ID: 25368246
[TBL] [Abstract][Full Text] [Related]
27. A Retrospective Multi-Institutional Cohort Analysis of Clinical Characteristics and Outcomes in Dedifferentiated Chondrosarcoma.
Bui N; Dietz H; Farag S; Hirbe AC; Wagner MJ; Van Tine BA; Ganjoo K; Jones RL; Keedy VL; Davis EJ
Cancers (Basel); 2023 May; 15(9):. PubMed ID: 37174084
[TBL] [Abstract][Full Text] [Related]
28. Functional profiling of receptor tyrosine kinases and downstream signaling in human chondrosarcomas identifies pathways for rational targeted therapy.
Zhang YX; van Oosterwijk JG; Sicinska E; Moss S; Remillard SP; van Wezel T; Bühnemann C; Hassan AB; Demetri GD; Bovée JV; Wagner AJ
Clin Cancer Res; 2013 Jul; 19(14):3796-807. PubMed ID: 23714727
[TBL] [Abstract][Full Text] [Related]
29. Mutation of p53 with loss of heterozygosity in the osteosarcomatous component of a dedifferentiated chondrosarcoma.
Grote HJ; Schneider-Stock R; Neumann W; Roessner A
Virchows Arch; 2000 May; 436(5):494-7. PubMed ID: 10881744
[TBL] [Abstract][Full Text] [Related]
30. Three new chondrosarcoma cell lines: one grade III conventional central chondrosarcoma and two dedifferentiated chondrosarcomas of bone.
van Oosterwijk JG; de Jong D; van Ruler MA; Hogendoorn PC; Dijkstra PD; van Rijswijk CS; Machado I; Llombart-Bosch A; Szuhai K; Bovée JV
BMC Cancer; 2012 Aug; 12():375. PubMed ID: 22928481
[TBL] [Abstract][Full Text] [Related]
31. Dedifferentiated chondrosarcomas arising in preexisting osteochondromas.
Staals EL; Bacchini P; Mercuri M; Bertoni F
J Bone Joint Surg Am; 2007 May; 89(5):987-93. PubMed ID: 17473135
[TBL] [Abstract][Full Text] [Related]
32. Dedifferentiated Chondrosarcoma Demonstrating Osteosarcomatous Differentiation.
Dhinsa BS; DeLisa M; Pollock R; Flanagan AM; Whelan J; Gregory J
Oncol Res Treat; 2018; 41(7-8):456-460. PubMed ID: 29902785
[TBL] [Abstract][Full Text] [Related]
33. [Dedifferentiated chondrosarcoma. A study of 13 clinical cases and review of the literature].
Anract P; Tomeno B; Forest M
Rev Chir Orthop Reparatrice Appar Mot; 1994; 80(8):669-80. PubMed ID: 7638395
[TBL] [Abstract][Full Text] [Related]
34. Frequent mutation of the major cartilage collagen gene COL2A1 in chondrosarcoma.
Tarpey PS; Behjati S; Cooke SL; Van Loo P; Wedge DC; Pillay N; Marshall J; O'Meara S; Davies H; Nik-Zainal S; Beare D; Butler A; Gamble J; Hardy C; Hinton J; Jia MM; Jayakumar A; Jones D; Latimer C; Maddison M; Martin S; McLaren S; Menzies A; Mudie L; Raine K; Teague JW; Tubio JM; Halai D; Tirabosco R; Amary F; Campbell PJ; Stratton MR; Flanagan AM; Futreal PA
Nat Genet; 2013 Aug; 45(8):923-6. PubMed ID: 23770606
[TBL] [Abstract][Full Text] [Related]
35. Bone- and cartilage-forming tumors and ewing sarcoma: an update with a gnathic emphasis.
Stewart BD; Reith JD; Knapik JA; Chi AC
Head Neck Pathol; 2014 Dec; 8(4):454-62. PubMed ID: 25409851
[TBL] [Abstract][Full Text] [Related]
36. Pazolimus: pazopanib plus sirolimus following progression on pazopanib, a retrospective case series analysis.
Katz D; Azraq Y; Eleyan F; Gill S; Peretz T; Merimsky O
BMC Cancer; 2016 Aug; 16():616. PubMed ID: 27501793
[TBL] [Abstract][Full Text] [Related]
37. [Cytogenesis and histogenesis of malignant and semimalignant bone tumors].
Roessner A; Grundmann E
Veroff Pathol; 1984; 122():1-195. PubMed ID: 6091360
[TBL] [Abstract][Full Text] [Related]
38. Malignant bone tumors.
Gibbs CP; Weber K; Scarborough MT
Instr Course Lect; 2002; 51():413-28. PubMed ID: 12064130
[No Abstract] [Full Text] [Related]
39. Potential sampling error in fine needle aspiration biopsy of dedifferentiated chondrosarcoma: a report of 4 cases.
Rinas AC; Ward WG; Kilpatrick SE
Acta Cytol; 2005; 49(5):554-9. PubMed ID: 16334036
[TBL] [Abstract][Full Text] [Related]
40. Final Overall Survival Efficacy Results of Ivosidenib for Patients With Advanced Cholangiocarcinoma With IDH1 Mutation: The Phase 3 Randomized Clinical ClarIDHy Trial.
Zhu AX; Macarulla T; Javle MM; Kelley RK; Lubner SJ; Adeva J; Cleary JM; Catenacci DVT; Borad MJ; Bridgewater JA; Harris WP; Murphy AG; Oh DY; Whisenant JR; Lowery MA; Goyal L; Shroff RT; El-Khoueiry AB; Chamberlain CX; Aguado-Fraile E; Choe S; Wu B; Liu H; Gliser C; Pandya SS; Valle JW; Abou-Alfa GK
JAMA Oncol; 2021 Nov; 7(11):1669-1677. PubMed ID: 34554208
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
